title: Ovarian sertoli-leydig cell tumors: A multicenter long-term clinicopathological analysis of 27 patients.
abstract: OBJECTIVE
  Information on the clinical behavior of ovarian Sertoli-Leydig cell tumors (SLCTs) as well as its prognostic factors and optimal management is limited due to a substantially low incidence of the disease. Also, limited data is available regarding the role of chemotherapy in the management of SLCTs. The aim of the study is to evaluate clinicopathological features and outcome of patients with ovarian SLCTs.
  
  
  METHODS
  Twenty-seven patients with SLCT treated at two centers were reviewed retrospectively during 21 years.
  
  
  RESULTS
  The median age was 45 years (range, 16-81) and the mean follow-up time was 86 months (range, 16-181). Twenty-three patients had stage IA, three patients had IC, and one patient had stage II disease. Eleven tumors (41%) were well-differentiated and 16 (59%) tumors were intermediately differentiated. Nine patients underwent unilateral salpino-oophorectomy and one patient, with a history of infertility, underwent cystectomy for fertility preservation. Eight patients with intermediately differentiated types of SLCT received adjuvant systemic chemotherapy including the combination bleomycin, etoposide, and cisplatin (BEP). Recurrence occurred in one patient with intermediated differentiated type SLCT with heterologous elements. She received four cycles of BEP chemotherapy. Twelve months later, she underwent cytoreductive surgery and received six cycles of cisplatin plus carboplatin. She died 24 months after the initial diagnosis.
  
  
  CONCLUSIONS
  SLCTs of the ovary are usually in early stage, unilateral, and benign. Fertility-sparing surgery is the preferred option in young women. In the adjuvant treatment setting, although information about chemotherapy is limited, BEP is a commonly used regimen. The degree of differentiation and the presence of heterologous elements relate to a poor prognosis.
authors.affiliation: Department of Obstetrics and Gynecology, Ege University Medical School, Izmir, Turkey.
authors.forename: Levent
authors.initials: L
authors.lastname: Akman
authors.forename: Ibrahim Egemen
authors.initials: IE
authors.lastname: Ertas
authors.forename: Mehmet
authors.initials: M
authors.lastname: Gokcu
authors.forename: Mustafa Cosan
authors.initials: MC
authors.lastname: Terek
authors.forename: Muzaffer
authors.initials: M
authors.lastname: Sanci
authors.forename: Ulus Ali
authors.initials: UA
authors.lastname: Sanli
authors.forename: Osman
authors.initials: O
authors.lastname: Zekioglu
authors.forename: Ahmet Aydin
authors.initials: AA
authors.lastname: Ozsaran
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy; D010053:Ovary / Q000473:pathology; D012189:Retrospective Studies; D018310:Sertoli-Leydig Cell Tumor / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin